Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Immunology 2015
Charcot-Marie-Tooth 1A: a narrative review with clinical and anatomical perspectives.
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Optical Coherence Tomography: A Potential Noninvasive Follow-up Tool in Multiple Sclerosis.
Interrater Reliability of Four Sensory Measures in People with Multiple Sclerosis.
Dimethyl fumarate for multiple sclerosis.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Episode 14 with Professor Gavin Giovannoni on the Epstein-Barr Virus (EBV).
Dimethylfumarate Impairs Neutrophil Functions.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.
Activity-Dependent and Experience-Driven Myelination Provide New Directions for the Management of Multiple Sclerosis.
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Relationship between disease-modifying therapy and depression in multiple sclerosis.
Webinar: "Seeking Best Practices in Classifier Construction and Testing"
Randomized study combining interferon & glatiramer acetate in multiple sclerosis.
Multiple sclerosis: pathogenesis and treatment.
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.
Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].

Pages